Company intelligence / Profile preview

Amylon Therapeutics

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Amylon Therapeutics develops RNA-based therapies targeting rare genetic central nervous system disorders. Its lead program focuses on HCHWA-D/Katwijk’s disease using ASO technology to modulate APP mRNA splicing. The company has several additional preclinical programs targeting neurodegenerative diseases and spinal muscular atrophy. No clinical results have been published yet.

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotides (ASOs)RNA-based therapeuticsBiological products
Industry: Biotech

Drug pipeline

1 asset

APH-1104

Preclinical

Partnerships

ProQR Therapeutics NV—licensing agreement and majority shareholder.

Beyond the preview

Go deeper on Amylon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amylon Therapeutics.

Explore the full profile